JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

MAY 1 2 2005

FILED CLERK'S OFFICE

DOCKET NO. 1456

BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE **LITIGATION**

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO-21)

On April 30, 2002, the Panel transferred 16 civil actions to the United States District Court for the District of Massachusetts for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. Since that time, 35 additional actions have been transferred to the District of Massachusetts. With the consent of that court, all such actions have been assigned to the Honorable Patti B. Saris.

It appears that the actions on this conditional transfer order involve questions of fact which are common to the actions previously transferred to the District of Massachusetts and assigned to Judge Saris.

Pursuant to Rule 7.4 of the Rules of Procedure of the Judicial Panel on Multidistrict Litigation, 199 F.R.D. 425, 435-36 (2001), these actions are transferred under 28 U.S.C. § 1407 to the District of Massachusetts for the reasons stated in the order of April 30, 2002, 201 F.Supp.2d 1378 (J.P.M.L. 2002), and, with the consent of that court, assigned to the Honorable Patti B. Saris.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of Massachusetts. The transmittal of this order to said Clerk shall be stayed fifteen (15) days from the entry thereof and if any party files a notice of opposition with the Clerk of the Panel within this fifteen (15) day period, the stay will be continued until further order of the Panel

Inasmuch as no objection is pending at this time, the stay is lifted. MAY 3 1 2005 **CLERK'S OFFICE** JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

FOR THE PANEL:

Clerk of the Panel

SCHEDULE CTO-21 - TAG-ALONG ACTIONS DOCKET NO. 1456 IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

DIST. DIV. C.A. #	CASE CAPTION				
NEW YORK NORTHERN					
NYN 1 05-408	The County of Washington v. Abbott Laboratories, Inc., et al.				
NYN 1 05-422	County of Rensselaer v. Abbott Laboratories, Inc., et al.				
NYN 1 05-425	County of Albany v. Abbott Laboratories, Inc., et al.				
NYN 1 05-468	County of Warren v. Abbott Laboratories, Inc., et al.				
NYN 1 05-474	County of Greene v. Abbott Laboratories, Inc., et al.				
NYN 1 05-478	County of Saratoga v. Abbott Laboratories, Inc., et al.				
NYN 3 05-354	County of Chenango v. Abbott Laboratories, Inc., et al.				
NYN 3 05-456	The County of Broome v. Abbott Laboratories, Inc., et al.				
NYN 5 05-397	County of Tompkins v. Abbott Laboratories, Inc., et al.				
NYN 5 05-423	County of Cayuga v. Abbott Laboratories, Inc., et al.				
NYN 6 05-415	County of Herkimer, New York v. Abbott Laboratories, Inc., et al.				
NYN 6 05-489	County of Oneida v. Abbott Laboratories, Inc., et al.				
NYN 7 05-479	County of Saint Lawrence v. Abbott Laboratories, Inc., et al.				
NEW YORK WESTERN					
NYW 1 05-214	County of Chautaugua y Abbatt of Laboratorias Inc. et al.				
NYW 1 05-214 NYW 1 05-236	County of Chautauqua v. Abbott of Laboratories, Inc., et al.				
NYW 1 05-256	County of Allegany v. Abbott Laboratories, Inc., et al.				
	County of Cattaraugus v. Abbott Laboratories, Inc., et al.				
NYW 1 05-259	County of Erie v. Abbott Laboratories, Inc., et al. Opposed 5/24/05				
NYW 6 05-6138	County of Wayne v. Abbott Laboratories, et al.				
NYW 6 05-6148	County of Monroe v. Abbott Laboratories, Inc., et al.				
NYW 6 05-6172	County of Yates v. Abbott Laboratories, Inc., et al.				

U.S. District Court Northern District of New York [LIVE - Version 2.4] (Syracuse) CIVIL DOCKET FOR CASE #: 5:05-cv-00397-GLS-GJD

County of Tompkins v. Abbott Laboratories, Inc. et al

Assigned to: Judge Gary L. Sharpe

Referred to: Magistrate Judge Gustave J. DiBianco

Cause: 42:1396 - Tort Negligence

Date Filed: 03/31/2005 Jury Demand: Plaintiff

Nature of Suit: 890 Other Statutory

Actions

Jurisdiction: Federal Question

Plaintiff

County of Tompkins

represented by Aaron D. Hovan

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600

Fax: 212-751-2540

Email: ahovan@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Joanne M. Cicala

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600 Fax: 212-751-2540

Email: jcicala@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Roger W. Kirby

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600

Fax: 212-751-2540

Email: iramirez@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

V.

Defendant

Abbott Laboratories, Inc.

1 of 9 6/7/2005 3:59 PM



Biovail Pharmaceuticals, Inc.

Defendant

Boehringer Ingelheim Corp.

Defendant

Boehringer Ingelheim

Pharmaceuticals, Inc.

Defendant

Bristol-Meyers Squibb Company

Defendant

Dermik Laboratories, Inc.

Defendant

Dey, Inc.

Defendant

Eisai, Inc.

Defendant

Eli Lilly and Company

Defendant

Endo Pharmaceuticals, Inc.

Defendant

Ethex Corp.

Defendant

Forest Laboratories, Inc.

Defendant

Forest Pharmaceuticals, Inc.

Defendant

Fujisawa Healthcare, Inc.

Defendant

Fujisawa USA, Inc.

Defendant

Genentech, Inc.

<u>Defendant</u>
Genzyme Corp.
Defendant
Gilead Sciences, Inc.
Defendant
Glaxosmithkline, P.L.C.
Defendant
Greenstone, Ltd.
<u>Defendant</u>
Hoffman-La Roche, Inc.
<u>Defendant</u>
Immunex Corp.
<u>Defendant</u>
Ivax Corp.
<u>Defendant</u>
Ivax Pharmaceuticals, Inc.
Defendant
Janssen Pharmaceutica Products, LP
<u>Defendant</u>
Johnson & Johnson
<u>Defendant</u>
King Pharmaceuticals, Inc.
Defendant
McNeil-PPC, Inc.
<u>Defendant</u>
Medimmune, Inc.
<u>Defendant</u>
Merck & Co., Inc.
<u>Defendant</u>

Monarch Pharmaceuticals, Inc.

Mylan Laboratories, Inc.

Defendant

Mylan Pharmaceuticals, Inc.

Defendant

Novartis Pharmaceuticals Corp.

Defendant

Novo Nordisk Pharmaceuticals, Inc.

Defendant

Oncology Therapeutics Network

Corp.

Defendant

Organon Pharmaceuticals USA, Inc.

Defendant

Ortho Biotech Products LP

Defendant

Ortho-McNeil Pharmaceutical, Inc.

Defendant

Par Pharmaceutical, Inc.

Defendant

Pfizer, Inc.

Defendant

Pharmacia Corp.

Defendant

Purdue Pharma, L.P.

Defendant

Purepac Pharmaceutical Co.

Defendant

Reliant Pharmaceuticals

Defendant

Roche Laboratories, Inc.

Roxane Laboratories, Inc.

Defendant

Sandoz, Inc.

Defendant

Sanofi-Synthelabo, Inc.

Defendant

Schering Corp.

Defendant

Schering-Plough Corp.

Defendant

Serono, Inc.

Defendant

Smithklinebeecham Corp.

doing business as Glaxosmithkline

Defendant

Takeda Pharmaceuticals North

America, Inc.

Defendant

Tap Pharmaceutical Products, Inc.

Defendant

Teva Pharmaceutical USA, Inc.

Defendant

UCB Pharma, Inc.

<u>Defendant</u>

UDL Laboratories, Inc.

Defendant

Warrick Pharmaceuticals Corp.

Defendant

Watson Pharmaceuticals, Inc.

Watson Pharma, Inc.

Defendant

Wyeth

Date Filed	#	Docket Text	
03/31/2005	1	COMPLAINT against Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr Laboratories, Inc., Baxter International, Inc., Baxter Healthcare Corporation, Bayer Corp., Ben Venue Laboratories, Inc., Berlex Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Gilead Sciences, Inc., Glaxosmithkline, P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Johnson & Johnson, King Pharmaceuticals, Inc., McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceutical, Inc., Par Pharmaceutical, Inc., Pfizer, Inc., Pharmacia Corp., Purdue Pharma, L.P., Purepac Pharmaceutical Co., Reliant Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sanofi-Synthelabo, Inc., Abbott Laboratories, Inc., Schering Corp., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceuticals, Inc., Watson Pharma, Inc., UDL Laboratories, Inc., Agouron Pharmaceuticals, Inc., Watson Pharma, Inc., Wyeth, Alcon Laboratories, Inc., Allergan, Inc. (Filing fee \$ 250 receipt number ALB000649) filed by County of Tompkins. (Attachments: # 1 Exhibit(s) Page 35-74# 2 Exhibit(s) Page 75-114# 3 Exhibit(s) A part 3# 2 Exhibit(s) A part 5# 9 Exhibit(s) A part 3# 2 Ex	
03/31/2005		Summons Issued as to Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr	

		Laboratories, Inc., Baxter International, Inc., Baxter Healthcare Corporation, Bayer Corp., Ben Venue Laboratories, Inc., Berlex Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Gilead Sciences, Inc., Glaxosmithkline, P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Johnson & Johnson, King Pharmaceuticals, Inc., McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceutical, Inc., Par Pharmaceutical, Inc., Pfizer, Inc., Pharmacia Corp., Purdue Pharma, L.P., Purepac Pharmaceutical Co., Reliant Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sanofi-Synthelabo, Inc., Abbott Laboratories, Inc., Schering Corp., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceutical USA, Inc., UCB Pharma, Inc., UDL Laboratories, Inc., Agouron Pharmaceuticals, Inc., Warrick Pharmaceuticals Corp., Watson Pharmaceuticals, Inc., Watson Pharma, Inc., Wyeth, Alcon Laboratories, Inc., Allergan, Inc., (ban) (Entered: 04/01/2005)	
03/31/2005	2	G.O. 25 FILING ORDER ISSUED Initial Conference set for 8/3/2005 02:30 PM in Syracuse before Magistrate Judge Gustave J. DiBianco. Civil Case Management Plan due by 7/25/2005. (ban) (Entered: 04/01/2005)	
04/28/2005		CLERK'S CORRECTION OF DOCKET ENTRY - Exhibit A Part 3 and Exhibit C to the 1 complaint were corrupted. Exhibits have been rescanned and properly uploaded. (jel,) (Entered: 04/28/2005)	
05/03/2005	3	Letter from Aaron Hovan, outside counsel for County of Tompkins requesting Adjournment of Deadlines. (Hovan, Aaron) (Entered: 05/03/2005)	
05/04/2005	4	ORDER: granting the # 3 Letter Request filed by County of Tompkins. The Clerk terminated the Rule 16 conference and the civil case management plan deadlines. Status Report deadline set for 12/15/2005. Signed by Judge Gustave J. DiBianco on 5/4/05. (jmb) (Entered: 05/05/2005)	
05/19/2005	<u>5</u>	NOTICE advising of Conditional Transfer. (alh) (Entered: 05/19/2005)	

	PACI	ER Service	Center				
Transaction Receipt							
06/07/2005 15:59:21							
PACER Login:	us2510	Client Code:					
Description:	Docket Report	Search Criteria:	5:05-cv-00397-GLS-GJD				
Billable Pages:	4	Cost:	0.32				